Chiung-Tong CHEN

Prof. Dr. Chiung-Tong CHEN

National Health Research Institutes, Miaoli, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in Cancer Research
Verified
Journal Article
Open access
PDF file
CKChing-Chuan Kuo
Ching-Chuan Kuo
HHHsing-Pang Hsieh
Hsing-Pang Hsieh
WPWen-Yu Pan
Wen-Yu Pan
CCChing-Ping Chen
Ching-Ping Chen
JLJing-Ping Liou
Jing-Ping Liou
JCJang-Yang Chang
Jang-Yang Chang
BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. BPR0L075 inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC50 values in single-digit nanomolar ranges. As determined by flow cytometry, human cervical carcinoma KB cells are arrested in G2-M phases in a time-dependent manner before cell death occurs. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway. Additional studies indicate that the effect of BPR0L075 on cell cycle arrest is associated with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C. The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis. Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075. Moreover, BPR0L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at i.v. doses of 50 mg/kg in nude mice. These findings indicate BPR0L075 is a promising anticancer compound with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance.

20 August 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
HHHui-Chen Hung
Hui-Chen Hung
YKYi-Yu Ke
Yi-Yu Ke
SHSheng Yu Huang
Sheng Yu Huang
PHPeng-Nien Huang
Peng-Nien Huang
YKYu-An Kung
Yu-An Kung
JHJohn Tsu-An Hsu
John Tsu-An Hsu
The coronavirus (CoV) disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is a health threat worldwide. Viral main protease (M pro , also called 3C‐like protease [3CL pro ]) is a therapeutic target for drug discovery. Herein, we report that GC376, a broad-spectrum inhibitor targeting M pro in the picornavirus-like supercluster, is a potent inhibitor for the M pro encoded by SARS-CoV-2, with a half-maximum inhibitory concentration (IC 50 ) of 26.

1 August 2020 in Biomedical Journal
Verified
Journal Article
Open access
CYCheng-Wei Yang
Cheng-Wei Yang
TPTzu-Ting Peng
Tzu-Ting Peng
HHHsing-Yu Hsu
Hsing-Yu Hsu
YLYue-Zhi Lee
Yue-Zhi Lee
SWSzu-Huei Wu
Szu-Huei Wu
SLShiow-Ju Lee
Shiow-Ju Lee
New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC50) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively. Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC50 values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.

19 February 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WLWen-Tai Li
Wen-Tai Li
DHDer-Ren Hwang
Der-Ren Hwang
JSJen-Shin Song
Jen-Shin Song
CCChing-Ping Chen
Ching-Ping Chen
JCJiunn-Jye Chuu
Jiunn-Jye Chuu
CCChiung-Tong CHEN
Chiung-Tong CHEN

1 September 2015 in Biomaterials
Verified
Journal Article
Closed access
Er-Yuan ChuangEr-Yuan Chuang
Er-Yuan Chuang
KLKun-Ju Lin
Kun-Ju Lin
PLPo-Yen Lin
Po-Yen Lin
HCHsin-Lung Chen
Hsin-Lung Chen
SWShiaw-Pyng Wey
Shiaw-Pyng Wey
HSHsing-Wen Sung
Hsing-Wen Sung

6 January 2007 in Journal of Biomedical Science
Verified
Journal Article
Closed access
PDF file
JCJiunn-Jye Chuu
Jiunn-Jye Chuu
JLJacqueline Ming Liu
Jacqueline Ming Liu
MTMei-Hua Tsou
Mei-Hua Tsou
CHChen-Lung Huang
Chen-Lung Huang
CCChing-Ping Chen
Ching-Ping Chen
CCChiung-Tong CHEN
Chiung-Tong CHEN